Enter your email address in the box to the right of this page to receive email updates from the Life Sciences Hub when new content is published.
For those with an interest in life sciences, the rise to prominence of CRISPR, a transformational development in the field of molecular biology and genetics, has been impossible to ignore.
Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
11 September 2019 - Posted by: Marc Döring
Late in 2018, medicinal cannabis was downgraded from Schedule 1 to Schedule 2 (medically allowed) in the Misuse of Drugs Regulations in the UK. The resulting flurry of activity in the mainstream news media about the use of cannabinoids and similar substances has been inescapable. Whilst there is arguably still a lot of hype around › Read More
03 September 2019 - Posted by: David Shen
On 26 August 2019, the China’s National People’s Congress passed the amended Drug Administration Law (the Amended DAL) which will take effect on 1 December. The new law brings in some changes while codifying many existing practices. We summarise in this article the key highlights, including intellectual property related rules, of the Amended DAL. 1. Redefine › Read More
02 September 2019 - Posted by: Kaat Van Delm
On 18 July 2019, the Belgian Constitutional Court suspended Article 3.2 of the legislation applicable to shortages of medicines in Belgium, after receiving multiple applications for both suspension and annulment of the Article. The Article obliged Belgian wholesale distributors to only supply their medicines for human use to other Belgian wholesale distributors, licensed pharmacies or › Read More
30 August 2019 - Posted by: Eveline Van Keymeulen
On 3 July 2019, a new Decree was published which modifies the evaluation procedure of generic and biosimilar medicines by the Transparency Commission of the High Health Authority (HAS). This Decree seeks to simplify the assessment procedures of such medicines in order to speed up their financing by French Social Security. The principle set out › Read More
28 August 2019 - Posted by: Eda Zhuleku
The new Law for More Safety in the Supply of Pharmaceuticals in Germany (Gesetz für mehr Sicherheit in der Arzneimittelversorgung- GSAV) which has been in force since 16 August amends the law regarding the prescription and sale of medical cannabis in Germany. Since 10 March 2017, it has been possible for medical cannabis to be prescribed › Read More